Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.

Grossi F, Genova C, Rijavec E, Barletta G, Biello F, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J.

Lung Cancer. 2018 Mar;117:64-69. doi: 10.1016/j.lungcan.2017.12.007. Epub 2017 Dec 13.

2.

A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.

Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H.

Cancer Immunol Res. 2018 Jan;6(1):79-86. doi: 10.1158/2326-6066.CIR-17-0412. Epub 2017 Dec 5.

PMID:
29208646
3.

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.

Grossi F, Rijavec E, Genova C, Barletta G, Biello F, Maggioni C, Burrafato G, Sini C, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J.

Br J Cancer. 2017 Jan 3;116(1):36-43. doi: 10.1038/bjc.2016.387. Epub 2016 Nov 29.

4.

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, De Pas T, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsypin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H.

Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13.

5.

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.

Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E.

Cancer Med. 2014 Jun;3(3):572-9. doi: 10.1002/cam4.208. Epub 2014 Feb 12.

6.

A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.

Stinchcombe TE, Roder J, Peterman AH, Grigorieva J, Lee CB, Moore DT, Socinski MA.

J Thorac Oncol. 2013 Apr;8(4):443-51. doi: 10.1097/JTO.0b013e3182835577. Erratum in: J Thorac Oncol. 2013 Jun;8(6):814.

7.

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.

Gautschi O, Dingemans AM, Crowe S, Peters S, Roder H, Grigorieva J, Roder J, Zappa F, Pless M, Brutsche M, Baty F, Bubendorf L, Hsu Schmitz SF, Na KJ, Carbone D, Stahel R, Smit E.

Lung Cancer. 2013 Jan;79(1):59-64. doi: 10.1016/j.lungcan.2012.10.006. Epub 2012 Nov 1.

PMID:
23122759
8.

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.

Kuiper JL, Lind JS, Groen HJ, Roder J, Grigorieva J, Roder H, Dingemans AM, Smit EF.

Br J Cancer. 2012 Nov 20;107(11):1820-5. doi: 10.1038/bjc.2012.470. Epub 2012 Oct 18.

9.

Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.

Carbone DP, Ding K, Roder H, Grigorieva J, Roder J, Tsao MS, Seymour L, Shepherd FA.

J Thorac Oncol. 2012 Nov;7(11):1653-60. doi: 10.1097/JTO.0b013e31826c1155.

10.

Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.

Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Viganò MG, Sorlini C, Ghio D, Tsypin M, Bulotta A, Bergamaschi L, Gregorc V.

J Thorac Oncol. 2012 Jan;7(1):40-8. doi: 10.1097/JTO.0b013e3182307f17.

11.

In situ mass spectrometry of autoimmune liver diseases.

Bowlus CL, Seeley EH, Roder J, Grigorieva J, Roder H, Caprioli RM, Gershwin M.

Cell Mol Immunol. 2011 May;8(3):237-42. doi: 10.1038/cmi.2010.72. Epub 2011 Jan 24.

12.

Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.

Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. doi: 10.1158/1055-9965.EPI-09-0937. Epub 2010 Jan 19.

13.

Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS.

Sanders ME, Dias EC, Xu BJ, Mobley JA, Billheimer D, Roder H, Grigorieva J, Dowsett M, Arteaga CL, Caprioli RM.

J Proteome Res. 2008 Apr;7(4):1500-7. doi: 10.1021/pr7008109. Epub 2008 Apr 4.

14.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP.

J Natl Cancer Inst. 2007 Jun 6;99(11):838-46.

PMID:
17551144
15.

Supplemental Content

Loading ...
Support Center